Circio Holding ASA: Registration of share capital increase following directed issue of NOK 3.6 million

Summary by AI ^BETAClose X

Circio Holding ASA has registered a share capital increase following a directed issue of NOK 3.6 million, bringing its new share capital to NOK 128,944,012.20, comprising 214,906,687 shares each with a nominal value of NOK 0.60. These new shares are expected to be issued and delivered today, 17 February 2026.

Disclaimer*

Oslo, 17 February 2026: Reference is made to the stock exchange announcement published by Circio Holding ASA (the “Company”) on 6 February 2026, regarding the directed issue of NOK 3.6 million (the “Directed Issue“).

The share capital increase related to the Directed Issue has been registered with the Norwegian Register of Business Enterprises today, 17 February 2026.

The Company’s new share capital is NOK 128,944,012.20 divided into 214,906,687 shares, each with a nominal value of NOK 0.60. The shares are expected to be issued and delivered today, 17 February 2026.

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology program, TG01, through cost-efficient external academic and industry collaborations. TG01 targets RAS-mutated cancers and is being tested in two clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine adjuvanted by STIMULON QS-21 licensed from Agenus Inc.